Loading...
  • tumors
  • Thiotepa has been used in the treatment of many types of tumors, but it is most often used as a treatment for the advanced stages of breast cancer , ovarian cancer , the middle and late stages of bladder cancer , and to control body cavity effusions, such as pleural effusion and pericardial effusion , that occur with some cancers. (encyclopedia.com)
  • patients
  • After surgical removal of a tumor, thiotepa has been shown to reduce the size of the remaining tumor in 29% of bladder cancer patients. (encyclopedia.com)
  • No patients have reported taking Thiotepa. (patientslikeme.com)
  • Patients will be monitored for an allergic-type reaction that may occur, although uncommonly, when treated with thiotepa. (unm.edu)
  • Patients will usually have scheduled meetings with their healthcare provider while they are being treated with thiotepa. (unm.edu)
  • Patients will also be monitored for a condition called hemorrhagic cystitis (bleeding from the bladder), which is uncommon, with treatment of thiotepa administered into the bladder. (unm.edu)
  • What are the common (occur in 30% or more of patients) side effects of treatment with thiotepa? (unm.edu)
  • What are the less common (occur in 10% to 29% of patients) side effects of treatment with thiotepa? (unm.edu)
  • Patients treated with thiotepa are at a slightly increased risk of developing a secondary malignancy. (unm.edu)
  • With thiotepa, this complication is utilised to clinical benefit to destroy haematopoietic progenitor cells in the bone marrow of patients requiring bone-marrow transplant. (guidetopharmacology.org)
  • PURPOSE: This phase I/II trial is studying the side effects of total-body irradiation, fludarabine, and thiotepa and to see how well they work in treating young patients who are undergoing a donor stem cell transplant for hematologic cancer. (clinicaltrials.gov)
  • Determine the safety of a conditioning regimen without anti-thymocyte globulin comprising total body irradiation, thiotepa, and fludarabine followed by CD34-positive-selected haploidentical allogeneic peripheral blood stem cell transplantation in young patients with life-threatening hematologic malignancies. (clinicaltrials.gov)
  • All patients receive fludarabine IV once daily on days -6 to -2 and thiotepa IV over 2 hours twice on day -5. (clinicaltrials.gov)
  • In patients with moderate renal impairment, (Creatinine clearance 30 ml/min to 59 ml/min) decreased renal excretion may lead to increased plasma levels of Thiotepa and TEPA, which may lead to increased toxicity. (luminanthealthcare.com)
  • In patients with moderate to severe renal impairment (Creatinine clearance less than 30 ml/min), close monitoring for the signs and symptoms of toxicity should be done for an extended period of time following the treatment with Thiotepa. (luminanthealthcare.com)
  • In general, caution should be exercised while administering Thiotepa in elderly patients since an increase in age is related to reduced hepatic, renal and/or cardiac functions as well as presence of concomitant disease or treatment of concomitant disease. (luminanthealthcare.com)
  • Thiotepa has been used to prepare patients for transplantation of blood-making cells in the European Union (EU) since the late 1980s. (europa.eu)
  • dosage
  • However, if the need outweighs the risk, thiotepa may be used in low dosage, accompanied by appropriate testing. (drugs.com)
  • bone
  • The main side effect of thiotepa is bone marrow suppression resulting in leukopenia, thrombocytopenia and anemia. (wikipedia.org)
  • risk
  • Using thiotepa may increase your risk of developing other types of cancer, such as leukemia. (cigna.com)